Video

Q&A With Ayman Tourbah From University Hospital of Reims: Treatment For Progressive Multiple Sclerosis Still Lags Behind Relapsing Form

Author(s):

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form. That is starting to change as more therapies and medications work their way through the regulatory approval process.

Professor Ayman Tourbah from the University Hospital of Reims in France discussed what can be done to help level the playing field in the treatment of this form of the disease during the ECTRIMS conference in Barcelona.

While there are considerably more treatment options available for relapsing multiple sclerosis there is considerable research being conducted to help patients with primary progressive multiple sclerosis.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.